Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

Area of Science:

• Genetics
• Oncology
• Epidemiology

Background:

• Germline mutations in CDKN2A are a significant cause of familial melanoma.
• Assessing the generalizability and performance of predictive models for CDKN2A mutations is crucial for melanoma-prone families.

Purpose of the Study:

• To evaluate the MELPREDICT model's performance in a global cohort of familial melanoma cases.
• To determine if adding phenotypic risk factors or a history of pancreatic cancer improves prediction accuracy.

Main Methods:

• The MELPREDICT model was applied to 2116 familial melanoma cases from the international GenoMEL Consortium.
• The GenoMELPREDICT model was developed by incorporating phenotypic risk factors and pancreatic cancer history.
• Model performance was assessed using Area Under the Curve (AUC) and Net Reclassification Index (NRI).

Main Results:

• The original MELPREDICT model showed good performance (AUC 0.752).
• The GenoMELPREDICT model demonstrated similar performance (AUC 0.748).
• Adding a history of pancreatic cancer significantly improved GenoMELPREDICT's discriminatory ability (AUC 0.772, NRI 0.40), while phenotypic factors did not.

Conclusions:

• The MELPREDICT model is effective for predicting CDKN2A mutational status in familial melanoma.
• Incorporating pancreatic cancer history enhances the predictive accuracy of the GenoMELPREDICT model.
• GenoMELPREDICT serves as a valuable tool for identifying individuals who may benefit from genetic testing or cancer risk counseling.